Lipid metabolism disorders lead to podocyte injury through pathways such as lipid peroxidation, abnormal sphingolipid metabolism, and cholesterol accumulation.
Target Population
Patients with diabetes at risk of developing DKD.
Care Setting
Clinical research and nephrology.
Key Highlights
Podocyte injury is a key factor in the progression of DKD.
Lipid metabolism disorders are significant contributors to podocyte dysfunction and apoptosis.
Key regulatory pathways include SREBP1, PPARα, and NLRP3 inflammasome.
Guideline-Based Recommendations
Diagnosis
Monitor for persistent proteinuria and decreased glomerular filtration rate.
Management
Focus on lipid metabolism as a therapeutic target in DKD.
Monitoring & Follow-up
Assess lipid profiles and kidney function regularly.
Risks
Increased risk of end-stage renal disease due to podocyte damage.
Patient & Prescribing Data
Individuals with diabetes, particularly those showing early signs of DKD.
Interventions targeting lipid metabolism may delay DKD progression.
Clinical Best Practices
Implement strategies to maintain lipid homeostasis in patients with diabetes.
Regularly evaluate podocyte function and structure in DKD patients.
